Liquidia down after challenging regulatory exclusivity for rival's inhaled drug

Liquidia

22/08/2024 14:56

(Updates)
    ** Shares of Liquidia Corp  LQDA.O  down 2.61% at $9.72
    ** Co says it has filed litigation in the U.S. District
Court of the District of Columbia that challenges the decision
by the FDA to grant 3-year exclusivity to United Therapeutics
 UTHR.O  rival drug Tyvaso DPI
    ** The health regulator on Monday delayed traditional
approval for Liquidia's inhaled drug yutrepia and allowed only
tentative approval
    ** The final approval of the drug is currently delayed until
after the expiration of the exclusivity on May 23, 2025
    ** Stock down ~18% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))